Clinical trials: Recurrent Hepatocellular Cancer
Liver Cancer
Sho-Saiko-To Following Removal of Liver Cancer By Embolization in Treating Patients With Liver Cancer That Cannot Be Surgically Removed
RATIONALE: The Chinese herbal medicine Sho-saiko-to contains ingredients that may slow the growth of tumor cells and stimulate a person's immune system to help kill tumor cells.
- Trial name
- NCT00040898
- Testing
- Sho-saiko-to
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cancer
Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor
RATIONALE: When irradiated lymphocytes from a donor are infused into the patient they may help the patient's immune system kill cancer cells.
- Trial name
- NCT00161187
- Testing
- therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Hepatocellular Carcinoma Recurrent
A RCT of TNF and ENT in the Treatment of Long-term Prognosis With Hepatitis B-related HCC After Curative Resection
This study evaluates the addition of Tenofovir and Entecavir in the treatment of Hepatitis B-related hepatocellular carcinoma after curative resection in adults.
- Trial name
- NCT04392700
- Testing
- Tenofovir disoproxil fumarate 300mg, Entecavir 0.5 mg
- Where
- China
- Volunteers
- 706 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma, Circulating Tumor Cell
Value of Dynamic Monitoring of Early Recurrence of Hepatocellular Carcinoma After Radical Resection Based on CTCS
On the basis of previous retrospective studies, the Task Force will further optimize the CTCs longitudinal surveillance model and initially validate the subclonal origin (CTC-DNA) of recurrent/metastatic foci derived from CTCs at…
- Conditions
- Hepatocellular Carcinoma, Circulating Tumor Cell, Recurrence, Surgery
- Trial name
- NCT06317896
- Testing
- circulating tumor cells
- Where
- 3 sites in China
- Volunteers
- 82 people
- Sponsor
- Zhujiang Hospital
Colorectal Cancer, Islet Cell Tumor
Isolated Hepatic Perfusion With Melphalan in Treating Patients With Primary Unresectable Liver Cancer or Liver Metastases
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving drugs in different ways may kill more tumor cells.
- Conditions
- Colorectal Cancer, Islet Cell Tumor, Liver Cancer, Metastatic Cancer
- Trial name
- NCT00019786
- Testing
- isolated perfusion, melphalan, conventional surgery
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Hepatocellular Carcinoma
Adjuvant Immunotherapy With Toripalimab Following Curative-intent Ablation for Recurrent Hepatocarcinoma
This phase II study is to evaluate the efficacy of the adjuvant immunotherapy after curative-intent ablation for recurrent hepatocarcinoma
- Trial name
- NCT05240404
- Testing
- Toripalimab, Thermal ablation
- Where
- China
- Volunteers
- 116 people
- Sponsor
- Xiangya Hospital of Central South University
Hepatocellular Carcinoma
Anti-recurrence Treatment of Postresection on HCC Patients With MVI Presence and Over-expression of ASPH
The aim of this study is to explore the effect of Transarterial Chemoembolization (TACE) on the prognosis of patients with microvascular invasion presence(MVI) and overexpression of Aspartate-β-hydroxylase(ASPH).
- Trial name
- NCT02587884
- Testing
- TACE
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Recurrent Hepatocellular Carcinoma
Ablation Plus Tislelizumab Versus Ablation Alone for Intrahepatic Recurrent Early Stage HCC
This is a randomized, controlled, phase 2 study to assess the efficacy and safety of ablation followed by tislelizumab versus ablation alone in patients with early recurrent hepatocellular carcinoma.
- Trial name
- NCT04663035
- Testing
- Tislelizumab, Ablation
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Ming Zhao
Carcinoma, Carcinoma, Hepatocellular
Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery
This is an open-label，multi-center ，non-randomized ，single arm exploratory study . This clinical study is an investigator-initiated clinical trial（IIT ）.
- Conditions
- Carcinoma, Carcinoma, Hepatocellular, Liver Neoplasms, Digestive System Neoplasms
- Trial name
- NCT04962958
- Testing
- Hepatic arterial infusion chemotherapy, Folfox Protocol, Donafenib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Cancer
Aminocamptothecin in Treating Patients With Advanced Cancer of the Peritoneal Cavity
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of aminocamptothecin in treating patients with advanced…
- Trial name
- NCT00003548
- Testing
- aminocamptothecin colloidal dispersion
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- NYU Langone Health
Liver Cancer
Contrast-Enhanced CT and MRI in Diagnosing and Staging Liver Cancer Using UNOS Policy
RATIONALE: Diagnostic procedures, such as contrast-enhanced CT scan and contrast-enhanced MRI, may help find liver cancer and find out how far the disease has spread.
- Trial name
- ACRIN6690 (NCT01082224)
- Testing
- iodinated contrast dye, motexafin gadolinium, Eovist-enhanced MRI
- Where
- 9 sites in United States
- Volunteers
- 440 people
- Sponsor
- American College of Radiology Imaging Network
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
Erlotinib in Treating Patients With Unresectable Liver Cancer and Liver Dysfunction
Phase I trial to study the effectiveness of erlotinib in treating patients who have unresectable liver cancer and liver dysfunction.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT00047346
- Testing
- erlotinib hydrochloride, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Liver Cancer
Sorafenib and Vorinostat in Treating Patients With Advanced Liver Cancer
This phase I trial is studying the side effects and best dose of vorinostat when given together with sorafenib tosylate in treating patients with advanced liver cancer.
- Trial name
- NCT01075113
- Testing
- sorafenib tosylate, vorinostat
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Virginia Commonwealth University
Hepatocellular Carcinoma
RFA Versus SBRT for Recurrent Small HCC
Recurrence rate of hepatocellular carcinoma (HCC)after resection is as high as 65.0%-83.7%.The recurrence of HCC is the most important factor affecting prognosis.
- Trial name
- NCT04047173
- Testing
- stereotactic body radiotherapy (SBRT), Radiofrequency ablation (RFA)
- Where
- China
- Volunteers
- 166 people
- Sponsor
- Sun Yat-sen University
ORR,OS,PFS
Exploration of Sintilimab + Bevacizumab + AG Chemotherapy as First-Line Treatment for Unresectable Advanced/Metastatic Cholangiocarcinoma
Evaluation of Efficacy and Safety of Sintilimab Plus Bevacizumab and AG Regimen as First-Line Therapy in Patients with Surgically Ineligible Locally Advanced or Metastatic Cholangiocarcinoma Objectives: Primary Objective: To…
- Trial name
- NCT07328802
- Testing
- Sintilimab combined with bevacizumab and albumin-bound paclitaxel plus gemcitabine
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Liver Cancer, Liver Transplant
FOLFOX Plus Lenvatinib Adjuvant Therapy for Hepatocellular Carcinoma Post-Liver Transplantation
Liver transplantation not only removes the liver tumor (seed) but also eliminates the underlying diseased liver (soil), making it an essential therapeutic approach for hepatocellular carcinoma (HCC).
- Trial name
- NCT06409637
- Testing
- FOLFOX4 regimen, lenvatinib
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Hepatocellular Carcinoma, Neoplasm Metastasis
Capecitabine to Prevent Recurrence of Hepatocellular Carcinoma After Curative Resection
The purpose of this study is to determine whether capecitabine is effective to prevent disease recurrence after curative hepatic resection in patients with hepatocellular carcinoma.
- Trial name
- NCT00561522
- Testing
- Capecitabine, No other preventive treatment
- Where
- China
- Volunteers
- 290 people
- Sponsor
- Fudan University
Hepatocellular Carcinoma
Ablation in Combination With Lenvatinib and Anti-PD-1 Antibodies
Lenvatinib is an oral multi-target receptor tyrosine kinase inhibitor (TKI) inhibitor that mainly inhibits the Endothelial growth factor receptor (VEGFR) VEGFR-1,2,3; Fibroblast growth factor receptor, FGFR) FGFR-1,2,3,4…
- Trial name
- NCT05803928
- Testing
- lenvatinib + anti-PD-1 antibodies, ablation
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Hua Li
HCC - Hepatocellular Carcinoma
Treatment Selection by 3D Bioprinting Liver Model to Prevent Liver Cancer Recurrence
This study is a feasibility study about a test on adjuvant therapy for patients in hepatocellular carcinoma (HCC) with a higher risk of tumour recurrence after liver resection or ablation.
- Trial name
- NCT07839767
- Testing
- Liver-in-cube testing
- Where
- Hong Kong
- Volunteers
- 20 people
- Sponsor
- The University of Hong Kong
Breast Cancer, Colorectal Cancer
Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer
RATIONALE: Vaccines made from a person's white blood cells that have been treated in the laboratory may make the body build an immune response to kill tumor cells.
- Conditions
- Breast Cancer, Colorectal Cancer, Gallbladder Cancer, Gastric Cancer
- Trial name
- NCT00027534
- Testing
- TRICOM-CEA(6D)
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Michael Morse, MD